PSY
Desconocido
ESNATS: Embryonic Stem cell based Novel Alternative Testing Strategies
PROTEOSYS AG
participó en un
FP7:
"ESNATS aims at developing a novel toxicity test platform based on embryonic stem cells (ESC), especially human ESC (hESC), to accelerate dr...
Financiado
Financiado
NEUROCYPRES: Neurotransmitter Cys loop receptors structure function and disease
PROTEOSYS AG
participó en un
FP7:
Cys-loop receptors (CLRs) form a superfamily of structurally related neurotransmitter-gated ion channels, comprising nicotinic acetylcholine...
Financiado
Financiado
BETA-JUDO: Beta cell function in juvenile diabetes and obesity
PROTEOSYS AG
participó en un
FP7:
The number of individuals with obesity and type 2 diabetes mellitus (T2DM) is increasing. An alarming aspect is decline in age of onset of T...
Financiado
Financiado
DETECTIVE: Detection of endpoints and biomarkers of repeated dose toxicity using in vitro systems
PROTEOSYS AG
participó en un
FP7:
Assessment of repeated dose toxicity is a standard requirement in human safety evaluation and relies on animal testing as no alternatives ar...
Financiado
Financiado
FIGHT-MG: Myasthenias a group of immune mediated neurological diseases from etiology to therapy
PROTEOSYS AG
participó en un
FP7:
Myasthenia Gravis (MG) is a heterogeneous rare autoimmune neurological disease affecting the neuromuscular junction (NMJ). The molecular eve...
Financiado
Financiado
* No se disponen de datos de la empresa actual.